Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Net Margin: 2020-2025

Historic Net Margin for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to 0.83%.

  • Xeris Biopharma Holdings' Net Margin rose 2984.00% to 0.83% in Q3 2025 from the same period last year, while for Sep 2025 it was -5.88%, marking a year-over-year increase of 2781.00%. This contributed to the annual value of -27.00% for FY2024, which is 1098.00% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Net Margin of 0.83% as of Q3 2025, which was up 130.98% from -2.70% recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Net Margin peaked at 0.83% during Q3 2025, and registered a low of -308.95% during Q2 2021.
  • For the 3-year period, Xeris Biopharma Holdings' Net Margin averaged around -26.45%, with its median value being -29.00% (2024).
  • In the last 5 years, Xeris Biopharma Holdings' Net Margin slumped by 6,502bps in 2021 and then skyrocketed by 20,548bps in 2022.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Net Margin stood at -237.02% in 2021, then skyrocketed by 19,800bps to -39.01% in 2022, then surged by 885bps to -30.16% in 2023, then spiked by 2,166bps to -8.51% in 2024, then skyrocketed by 2,984bps to 0.83% in 2025.
  • Its Net Margin was 0.83% in Q3 2025, compared to -2.70% in Q2 2025 and -15.34% in Q1 2025.